ValiRx plc
VAL.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | £0 | £0 | £0 | £0 |
| % Growth | 418.5% | – | – | – |
| Cost of Goods Sold | £0 | £0 | £0 | £0 |
| Gross Profit | -£0 | -£0 | -£0 | -£0 |
| % Margin | -436.4% | -2,562.9% | – | – |
| R&D Expenses | £0 | £0 | £1 | £0 |
| G&A Expenses | £2 | £2 | £2 | £1 |
| SG&A Expenses | £2 | £2 | £2 | £1 |
| Sales & Mktg Exp. | £0 | -£0 | £0 | £0 |
| Other Operating Expenses | -£0 | £0 | £1 | £0 |
| Operating Expenses | £2 | £2 | £3 | £2 |
| Operating Income | -£2 | -£2 | -£3 | -£2 |
| % Margin | -4,302.7% | -23,943.1% | – | – |
| Other Income/Exp. Net | £0 | -£0 | -£0 | -£0 |
| Pre-Tax Income | -£2 | -£2 | -£3 | -£2 |
| Tax Expense | -£0 | -£0 | -£0 | -£0 |
| Net Income | -£2 | -£2 | -£2 | -£2 |
| % Margin | -3,848.7% | -21,226.1% | – | – |
| EPS | -0.015 | -0.02 | -0.031 | -0.024 |
| % Growth | 27.9% | 35.4% | -30.7% | – |
| EPS Diluted | -0.015 | -0.02 | -0.031 | -0.024 |
| Weighted Avg Shares Out | 132 | 102 | 77 | 65 |
| Weighted Avg Shares Out Dil | 132 | 102 | 77 | 65 |
| Supplemental Information | – | – | – | – |
| Interest Income | £0 | £0 | £0 | £0 |
| Interest Expense | £0 | £0 | £0 | £0 |
| Depreciation & Amortization | £0 | £0 | £0 | £0 |
| EBITDA | -£2 | -£2 | -£2 | -£1 |
| % Margin | -3,741.2% | -21,295.2% | – | – |